Burn–McKeown Syndrome: Disease-Characteristics Research Report

Executive summary

Burn–McKeown syndrome (BMKS) is an exceptionally rare, congenital, autosomal-recessive craniofacial spliceosomopathy caused by biallelic variants that reduce TXNL4A function. Bilateral choanal atresia or stenosis is the defining manifestation; hearing loss, cleft lip/palate, lower-eyelid coloboma, short palpebral fissures, a prominent high-bridged nose, short philtrum, large ears, and occasional cardiac or other visceral anomalies form the broader phenotype. Fewer than 20 affected families had been reported by 2020, precluding reliable prevalence, survival, penetrance, or quality-of-life estimates. (wood2020modellingthedevelopmental pages 1-5, wieczorek2014compoundheterozygosityof pages 1-2)

The usual molecular architecture is a hypomorphic 34-bp TXNL4A promoter deletion in trans with a rare loss-of-function allele. Reduced TXNL4A disrupts U4/U6.U5 tri-snRNP assembly and selectively changes pre-mRNA splicing. Patient-derived neural-crest models implicate diminished WNT signaling, abnormal TCF7L2 splicing, delayed epithelial-to-mesenchymal transition (EMT), and reduced proliferation; Xenopus knockdown additionally supports apoptosis-mediated depletion of cranial neural-crest progenitors. (wieczorek2014compoundheterozygosityof pages 7-8, wood2020modellingthedevelopmental pages 37-41, park2022thecoresplicing pages 7-10)

No disease-modifying treatment, validated biomarker, formal clinical guideline, or BMKS-specific interventional trial was identified. Current care is multidisciplinary and directed at airway obstruction, hearing impairment, clefting, cardiac defects, and other individual anomalies.

Table: This table condenses the main disease-level, genetic, mechanistic, diagnostic, and model-system findings for Burn-McKeown syndrome. It highlights established evidence and key quantitative details while preserving citations to the retrieved source contexts.

Evidence scope and currency

The principal human genetic evidence remains the 2014 American Journal of Human Genetics study of 11 families. The most detailed disease-specific mechanistic investigation is a May 2020 bioRxiv patient-iPSC study and should be treated as preprint evidence. The principal organismal BMKS model is a peer-reviewed 2022 Xenopus study. Searches prioritizing 2023–2024 identified no new BMKS-specific clinical cohort, natural-history study, therapeutic trial, or definitive molecular update; recent spliceosomopathy work remains largely contextual rather than BMKS-specific.

1. Disease information

Definition and classification

BMKS is a Mendelian congenital craniofacial developmental disorder, more specifically a U5-snRNP-related craniofacial spliceosomopathy or mandibulofacial dysostosis spectrum disorder. It was clinically recognized before its genetic cause was established; biallelic TXNL4A variants were demonstrated in 2014. (wieczorek2014compoundheterozygosityof pages 1-2)

Identifiers and synonyms

• OMIM: 608572.
• MONDO: A dedicated MONDO identifier was not verified in the retrieved primary literature; it should be resolved directly against the current MONDO release rather than inferred.
• Orphanet: Not verified from the retrieved evidence.
• ICD-10/ICD-11: No disease-specific code was identified. Coding generally requires congenital-malformation codes for choanal atresia and associated defects.
• MeSH: No dedicated BMKS descriptor was verified.
• Synonyms: Burn–McKeown syndrome; Burn-McKeown syndrome; BMKS; occasionally discussed in relation to oculo-oto-facial dysplasia, which may lie within the same phenotypic spectrum. (wieczorek2014compoundheterozygosityof pages 1-2)

The evidence is predominantly aggregated disease-level literature assembled from individually phenotyped families, not population EHR data. The 2014 study evaluated 11 families and found the relevant biallelic TXNL4A genotype in 9. (wieczorek2014compoundheterozygosityof pages 1-2, wieczorek2014compoundheterozygosityof pages 3-4)

Key abstract statement: the discovery report described BMKS as a rare autosomal-recessive condition “characterized by bilateral choanal atresia” with characteristic craniofacial anomalies and identified biallelic TXNL4A mutations. (wieczorek2014compoundheterozygosityof pages 1-2)

2. Etiology

Causal factor

The cause is genetic: insufficient TXNL4A dosage from biallelic germline variants. The common configuration combines a low-frequency promoter deletion with a severe coding or copy-number loss on the other chromosome. Heterozygous relatives can be unaffected, arguing against ordinary monoallelic haploinsufficiency. (wieczorek2014compoundheterozygosityof pages 4-6)

Genetic risk factors

• TXNL4A 34-bp promoter deletion D1/type 1: chr18:g.77,748,581_77,748,614del in the reference used by the 2014 report.
• D2/type 2: chr18:g.77,748,604_77,748,637del.
• Reported loss-of-function examples include c.349G>T, p.(Glu117Ter); c.37C>T, p.(Gln13Ter); and c.131delT, p.(Val44AlafsTer48).
• Larger terminal 18q deletions encompassing TXNL4A, ranging from approximately 0.484 to 4.7 Mb in the discovery series, can constitute one allele. (wieczorek2014compoundheterozygosityof pages 3-4, wieczorek2014compoundheterozygosityof pages 4-6)

The type-1 promoter deletion had an estimated allele frequency of 0.76% in the original study. Its predicted homozygous frequency was approximately 1 in 17,300, but homozygosity for that allele was not established as equivalent to classic BMKS; pathogenicity depends on allelic context and residual expression. (wieczorek2014compoundheterozygosityof pages 1-2, wieczorek2014compoundheterozygosityof pages 7-8)

Environmental, infectious, and lifestyle risk factors

No toxin, infection, diet, smoking, occupation, parental age, or lifestyle exposure has been demonstrated to cause or modify BMKS. It is not infectious or multifactorial on present evidence.

Protective factors and gene–environment interaction

No protective allele, environmental protective factor, modifier gene, or reproducible gene–environment interaction has been reported. Avoidance of ordinary environmental exposures cannot prevent the inherited developmental defect.

3. Phenotypes

All manifestations are congenital or developmentally determined. Exact percentages are unavailable for most findings because published cohorts are extremely small and ascertainment is non-uniform.

The clinical series also reported hypertelorism and inguinal hernia. Intellectual development is generally normal, so severe intellectual disability should prompt assessment for a larger deletion, blended diagnosis, complications, or expanded phenotype. (wood2020modellingthedevelopmental pages 1-5, wieczorek2014compoundheterozygosityof pages 3-4, wieczorek2014compoundheterozygosityof pages 2-3)

No BMKS-specific EQ-5D, SF-36, PROMIS, caregiver-burden, or disease-specific quality-of-life data were found. Quality-of-life effects above are clinically plausible consequences of the lesions, not measured BMKS outcomes.

4. Genetic and molecular information

Causal gene

TXNL4A at 18q23, also called DIB1, encodes an essential U5 small nuclear ribonucleoprotein component. A current HGNC identifier and transcript accession should be imported directly from HGNC/NCBI for production annotation because reference-transcript differences affect variant nomenclature.

Variant classes and interpretation

Established disease alleles include promoter deletions, nonsense and frameshift variants, splice-disrupting variants, intragenic/terminal copy-number deletions, and possibly other severe loss-of-function alleles. They are constitutional germline variants, not somatic mutations. The original severe coding variants were absent from 1000 Genomes, dbSNP, and approximately 3,000 control exomes available at the time. (wieczorek2014compoundheterozygosityof pages 4-6)

D1 and D2 reduced promoter activity by 59% and 72%, respectively. Classic BMKS therefore appears to require residual expression: a hypomorphic regulatory allele paired with a null allele, or an appropriate biallelic hypomorphic configuration. Complete biallelic null loss is considered likely incompatible with life because DIB1 is essential in experimental organisms. (wood2020modellingthedevelopmental pages 1-5, wieczorek2014compoundheterozygosityof pages 7-8)

Variant classifications should nevertheless be checked in current ClinVar and assessed using ACMG/AMP rules, including noncoding-variant guidance. A common promoter allele should not be called pathogenic in isolation; phase, second-allele severity, phenotype, segregation, and functional evidence are essential.

Modifiers, epigenetics, and chromosomal abnormalities

No validated modifier gene or BMKS-specific DNA-methylation/chromatin signature is known. Large 18q deletions may broaden the phenotype through contiguous-gene effects. No recurrent aneuploidy, balanced translocation, or inversion defines BMKS. (wieczorek2014compoundheterozygosityof pages 3-4, wieczorek2014compoundheterozygosityof pages 4-6)

5. Environmental information

No environmental toxin, radiation exposure, pollutant, occupational factor, diet, alcohol, smoking behavior, or infectious agent is causally associated with BMKS. Environmental influences may affect general pregnancy or postoperative outcomes but are not established components of disease etiology. CTD-style chemical–disease assertions should therefore not be populated as causal without separate evidence.

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic defect: biallelic TXNL4A alleles lower functional protein dosage.
2. Spliceosomal defect: insufficient TXNL4A/DIB1 compromises U5-snRNP and U4/U6.U5 tri-snRNP assembly and control of spliceosome activation.
3. Selective RNA-processing vulnerability: transcripts with particular exon/intron architecture and weaker splice sites are disproportionately mis-spliced rather than all transcripts failing uniformly.
4. Developmental signaling disturbance: neural-crest-relevant expression programs, cell adhesion, WNT/β-catenin signaling, and EMT become abnormal.
5. Cellular phenotype: reduced proliferation, delayed/failed neural-crest differentiation and EMT, and—in Xenopus—excess dorsal-ectoderm/neural-crest apoptosis deplete or impair cranial neural-crest progenitors.
6. Tissue phenotype: deficient formation of neural-crest-derived craniofacial cartilage, bone, and nasal/choanal structures produces choanal atresia and facial dysostosis. (wieczorek2014compoundheterozygosityof pages 7-8, wood2020modellingthedevelopmental pages 37-41, park2022thecoresplicing pages 1-2)

Human iPSC/iNCC evidence

Patient iPSCs proliferated 52% more slowly than maternal cells and 65% more slowly than unrelated controls, without increased apoptosis. RNA sequencing identified 1,181 differentially expressed genes and 1,511 alternative-splicing events in 1,096 genes; 1,154 were exon-skipping events. (wood2020modellingthedevelopmental pages 24-27, wood2020modellingthedevelopmental pages 21-24)

After neural-crest differentiation, there were 5,746 differentially expressed genes and 2,991 differential-splicing events in 2,029 genes; 88% of affected splicing events were iNCC-specific. Patient cells retained epithelial markers and had reduced mesenchymal/neural-crest markers, with an EMT score of −5 versus +5 in maternal and +8 in unrelated-control cells. Extending differentiation to 168 hours did not rescue the defect. (wood2020modellingthedevelopmental pages 34-37, wood2020modellingthedevelopmental pages 27-31, wood2020modellingthedevelopmental pages 69-74)

AXIN2 was downregulated (p=0.0004), supporting reduced WNT activation. Abnormal inclusion of TCF7L2 exon 4, which is associated with a dampened WNT response, was proposed as one mechanistic link. This is a leading model, not yet proof that TCF7L2 alone causes the human phenotype. (wood2020modellingthedevelopmental pages 34-37, wood2020modellingthedevelopmental pages 27-31)

Exact abstract excerpt from the 2020 preprint: “Patient iPSCs displayed defective differentiation into iNCCs … in particular a delay in undergoing an epithelial-to-mesenchymal transition (EMT).” The abstract further reports “a dampened response to WNT signalling” and identifies TCF7L2 exon-4 mis-splicing as a potential cause. (wood2020modellingthedevelopmental pages 1-5, wood2020modellingthedevelopmental pages 37-41)

Model-organism evidence

In Xenopus, 30-ng Txnl4a morpholino knockdown reduced sox10 in 85.7% and tfap2e in 32.4% of embryos; morpholino-resistant txnl4a increased normal sox10 expression from 14% to 62%, supporting specificity. TUNEL-positive apoptosis increased in dorsal ectoderm at stage 15 (n=41, p<0.0005), and 38% of stage-45 morphants showed craniofacial cartilage defects (p<0.0001). (park2022thecoresplicing pages 7-10, park2022thecoresplicing pages 4-7)

Ontology suggestions

• GO biological process: mRNA splicing via spliceosome; spliceosomal complex assembly; neural crest cell development; epithelial-to-mesenchymal transition; canonical WNT signaling; regulation of apoptotic process; craniofacial morphogenesis; cartilage development.
• GO cellular component: spliceosomal complex; U5 snRNP; U4/U6.U5 tri-snRNP; nucleus/nucleoplasm.
• Cell Ontology: neural crest cell; cranial neural crest cell; craniofacial chondrocyte; osteoblast progenitor; craniofacial mesenchymal cell. Exact CL identifiers should be ontology-validated before ingestion.

No BMKS-specific proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, epigenomic, organoid, or in-vivo CRISPR-screen dataset was identified. The iPSC experiment is bulk transcriptomic evidence from one family, a major limitation. (wood2020modellingthedevelopmental pages 37-41, wood2020modellingthedevelopmental pages 45-49)

7. Anatomical structures affected

Primary structures

• Posterior nasal apertures/choanae and nasal airway.
• Craniofacial skeleton and neural-crest-derived cartilage.
• Palate and lip.
• Eyelids and periocular region.
• External/middle/inner auditory system, depending on the basis of hearing loss.

Secondary or variable structures

Heart and great-vessel derivatives, kidney, anus/rectum, digits, feet, and inguinal region can be involved. (wieczorek2014compoundheterozygosityof pages 3-4, wieczorek2014compoundheterozygosityof pages 2-3)

Suggested anatomy terms: choana; nasal cavity; nasopharynx; palate; mandible; eyelid; external ear; middle ear; inner ear; craniofacial skeleton; heart; kidney; anus. Exact UBERON identifiers should be resolved against the active release. Bilateral involvement is characteristic for choanal atresia; other anomalies may be unilateral, bilateral, or asymmetric.

At the subcellular level, the primary compartment is the nuclear spliceosome, especially the U5 and U4/U6.U5 snRNP assemblies.

8. Temporal development

BMKS begins during embryogenesis and is clinically evident at birth. Bilateral choanal atresia can present acutely with neonatal respiratory compromise, whereas hearing, speech, dental, growth, and educational consequences become clearer through childhood.

The underlying malformations are stable congenital lesions rather than relapsing or degenerative disease. Functional morbidity may evolve with growth or after reconstructive procedures. There are no validated disease stages, progression rate, remission pattern, or longitudinal natural-history model. Critical developmental vulnerability probably coincides with cranial neural-crest specification, EMT, migration, and craniofacial morphogenesis; clinically, birth is the critical airway-intervention window. (wood2020modellingthedevelopmental pages 1-5, park2022thecoresplicing pages 7-10)

9. Inheritance and population

• Inheritance: autosomal recessive.
• Recurrence risk: when both parents carry relevant alleles, each pregnancy conventionally has a 25% probability of an affected child, 50% of a carrier, and 25% of inheriting neither familial allele, subject to confirmation of phase and variant pathogenicity.
• Penetrance: apparently high for appropriately damaging biallelic genotypes, but not numerically estimable.
• Expressivity: variable for clefting, hearing loss, heart/renal/anal defects, growth, and neurodevelopment.
• Anticipation: not expected and not reported.
• Germline mosaicism: not established.
• Consanguinity: can facilitate homozygosity; one consanguineous family was homozygous for the D2 promoter deletion. (wieczorek2014compoundheterozygosityof pages 1-2)
• Founder effect: no confirmed founder population was identified.
• Carrier frequency: cannot be equated with the 0.76% D1 allele frequency because multiple alleles and genotype-dependent pathogenicity are involved.

Fewer than 20 families were reported worldwide by 2020. No defensible cases-per-100,000 prevalence, annual incidence, geographic concentration, ethnic enrichment, age distribution, or sex ratio is available. (wood2020modellingthedevelopmental pages 1-5)

10. Diagnostics

Clinical recognition and immediate evaluation

Suspect BMKS in a neonate or child with bilateral choanal atresia/stenosis plus the characteristic oculo-oto-facial pattern, clefting, hearing loss, or congenital heart disease. Immediate priorities are airway patency, feeding, and cardiorespiratory stability.

A reasonable phenotype-directed work-up includes nasal endoscopy and thin-section CT for choanal anatomy; formal audiology; ophthalmologic assessment; cleft/craniofacial examination; echocardiography; renal ultrasonography; assessment for anal patency, feeding, growth, development, and speech. These are anomaly-directed clinical practices; no BMKS-specific consensus protocol was found.

Molecular testing

1. Preferred: a craniofacial/choanal-atresia panel or genome analysis that includes TXNL4A coding exons, splice regions, the recurrent promoter interval, and copy-number analysis.
2. WES: can identify coding loss-of-function alleles but may miss the 34-bp promoter deletion and some CNVs.
3. WGS: potentially best single assay because it can interrogate coding, promoter, and structural alleles, provided the pipeline calls and interprets the repetitive promoter region reliably.
4. Targeted testing: PCR/fragment analysis or Sanger sequencing for D1/D2 plus sequencing of coding/splice regions in a strongly suggestive case.
5. CMA/MLPA: useful when a deletion encompassing TXNL4A is suspected; the discovery study used microarray and MLPA.
6. Karyotype, FISH, mtDNA, and repeat-expansion testing have no routine disease-specific role unless another diagnosis is suspected. (wieczorek2014compoundheterozygosityof pages 3-4, wieczorek2014compoundheterozygosityof pages 4-6)

Confirm trans configuration through parental testing. RNA analysis or promoter functional studies may help resolve unusual splice/regulatory VUS but are not validated routine biomarkers.

Differential diagnosis

Important alternatives include CHARGE syndrome/CHD7 disorder; Treacher Collins syndrome (TCOF1, POLR1D, POLR1C); mandibulofacial dysostosis with microcephaly (EFTUD2); Nager syndrome (SF3B4); cerebro-costo-mandibular syndrome (SNRPB); Miller syndrome (DHODH); craniofacial microsomia; isolated choanal atresia; and 18q deletion syndromes. BMKS is favored by bilateral choanal atresia together with short palpebral fissures, lower-eyelid coloboma, prominent high-bridged nose, short philtrum, large ears, hearing loss, clefting, usually normal intellect, and biallelic TXNL4A variants. Oculo-oto-facial dysplasia may overlap the same spectrum. (wieczorek2014compoundheterozygosityof pages 2-3, wieczorek2014compoundheterozygosityof pages 1-2)

No biochemical, histopathologic, electrophysiologic, circulating, proteomic, metabolomic, or liquid-biopsy marker is established. There are no standardized diagnostic criteria beyond phenotype plus molecular confirmation.

11. Outcome and prognosis

No 5- or 10-year survival estimate, life expectancy, disease-specific mortality rate, disability score, or validated prognostic biomarker exists. The main immediate risk is neonatal airway obstruction from bilateral choanal atresia. Longer-term morbidity is expected to reflect restenosis or repeated airway procedures, hearing and speech impairment, cleft-related feeding/dental problems, and the severity of cardiac, renal, or anorectal anomalies.

Normal intellectual development is typical, but rare severe disability has been reported. Recovery means correction or adaptation to individual malformations; the constitutional molecular defect is lifelong. Prognosis is therefore anatomy-dependent rather than governed by a validated TXNL4A genotype score. (wood2020modellingthedevelopmental pages 1-5, wieczorek2014compoundheterozygosityof pages 2-3)

12. Treatment

There is no approved TXNL4A-directed therapy, pharmacotherapy, gene therapy, RNA therapy, cell therapy, or splice-correcting treatment.

Current clinical management

• Bilateral choanal atresia: emergency airway stabilization followed by definitive otolaryngologic repair, generally using an endoscopic transnasal approach according to anatomy and local expertise; monitor for restenosis.
• Hearing loss: serial audiology, hearing aids or bone-conduction devices as appropriate, and cochlear-implant assessment for severe sensorineural loss. Cochlear implantation was contemplated in reported BMKS care. (wieczorek2014compoundheterozygosityof pages 2-3)
• Cleft lip/palate: multidisciplinary craniofacial repair, feeding support, dental/orthodontic care, and speech-language therapy.
• Eyelid coloboma: ocular-surface protection and ophthalmic reconstruction when indicated.
• Cardiac, renal, anorectal, and hernia anomalies: standard specialty-specific surveillance and surgery.
• Development: early-intervention, educational, occupational, and speech support based on individual assessment.

Suggested NCIT intervention concepts include surgical procedure, reconstructive surgery, airway management, hearing aid, cochlear implantation, speech therapy, genetic counseling, and supportive care; exact NCIT codes should be terminology-validated.

No treatment-response rate, comparative surgical outcome, pharmacogenomic recommendation, or BMKS-specific adverse-event profile was found. The ClinicalTrials.gov search identified no relevant BMKS interventional study or NCT identifier.

The WNT/TCF7L2 and apoptosis findings are mechanistic research leads, not justification for prenatal or postnatal WNT- or apoptosis-targeted therapy. (wood2020modellingthedevelopmental pages 34-37, park2022thecoresplicing pages 7-10)

13. Prevention

Primary lifestyle or vaccine prevention is not applicable. Evidence-based prevention is reproductive and complication-focused:

• Offer genetic counseling and parental testing after molecular confirmation.
• Provide cascade testing to at-risk adult relatives for the known familial alleles.
• For a known familial genotype, discuss prenatal diagnosis by chorionic-villus sampling or amniocentesis and preimplantation genetic testing for monogenic disease.
• Ensure assays test both the promoter deletion and the family’s second allele.
• Targeted fetal imaging may detect clefting or major associated anomalies but cannot exclude BMKS or reliably establish choanal patency.
• Tertiary prevention consists of early airway treatment, newborn/serial hearing assessment, feeding support, cardiac and renal evaluation, and timely craniofacial intervention.

BMKS is not part of standard biochemical newborn screening, and population carrier screening is not established.

14. Other species and natural disease

No naturally occurring veterinary syndrome definitively homologous to human BMKS was identified, and there is no zoonotic or cross-species transmission. TXNL4A/DIB1 function is evolutionarily conserved. Experimental ortholog evidence exists in:

• Saccharomyces cerevisiae DIB1: depletion reduces U4/U6.U5 tri-snRNP assembly.
• Caenorhabditis elegans: null ortholog loss is reported as lethal in the disease-model literature.
• Xenopus laevis: experimentally reduced txnl4a produces neural-crest and craniofacial defects. (wood2020modellingthedevelopmental pages 1-5, wieczorek2014compoundheterozygosityof pages 7-8, park2022thecoresplicing pages 2-4)

These are induced models, not natural animal disease. Exact NCBI Taxonomy and ortholog Gene IDs should be imported from NCBI/Alliance rather than inferred here.

15. Model organisms and experimental systems

Yeast

Conditional DIB1 depletion models the upstream spliceosome defect and demonstrated impaired tri-snRNP assembly. It is powerful for molecular spliceosome biology but cannot model vertebrate neural crest or facial anatomy. (wieczorek2014compoundheterozygosityof pages 7-8)

Patient-derived iPSCs and induced neural-crest cells

Peripheral blood cells from one affected individual and her unaffected carrier mother were reprogrammed and compared with unrelated controls. This system recapitulated reduced proliferation, extensive mis-splicing, diminished WNT response, and delayed EMT during neural-crest differentiation. Its strengths are human genetic context and disease-relevant cell lineage; limitations include one family, a patient with atypical severe intellectual disability, non-isogenic controls, bulk RNA sequencing, and preprint publication status. (wood2020modellingthedevelopmental pages 37-41, wood2020modellingthedevelopmental pages 1-5, wood2020modellingthedevelopmental pages 45-49)

Xenopus

Morpholino knockdown at the two-cell stage reduced neural-crest markers, increased apoptosis, and produced craniofacial-cartilage defects; partial rescue with morpholino-resistant txnl4a supports on-target action. Limitations include transient knockdown, incomplete phenotype penetrance, dosage sensitivity, and absence of the precise human promoter/compound-heterozygous architecture. (park2022thecoresplicing pages 7-10, park2022thecoresplicing pages 2-4)

No published BMKS-specific knock-in mouse, zebrafish germline mutant, patient organoid, or isogenic CRISPR-corrected iPSC model was identified in the retrieved literature. The highest-value next steps are isogenic correction/introduction of D1 and D2 alleles, multiple-patient iPSC cohorts, single-cell time courses of cranial neural-crest differentiation, direct spliceosome-complex proteomics, and animal knock-in models reproducing human residual TXNL4A dosage.

Key publications

1. Wieczorek et al. “Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in TXNL4A causes Burn-McKeown syndrome.” American Journal of Human Genetics 95:698–707. Published December 2014. DOI/URL: https://doi.org/10.1016/j.ajhg.2014.10.014. This is the landmark human genetic and functional study. (wieczorek2014compoundheterozygosityof pages 1-2, wieczorek2014compoundheterozygosityof pages 4-6)
2. Wood et al. “Modelling the developmental spliceosomal craniofacial disorder Burn-McKeown syndrome using induced pluripotent stem cells.” bioRxiv preprint, posted May 14, 2020. DOI/URL: https://doi.org/10.1101/2020.05.13.094029. This is the principal patient-derived transcriptomic/mechanistic study but was retrieved as a preprint. (wood2020modellingthedevelopmental pages 1-5, wood2020modellingthedevelopmental pages 37-41)
3. Park et al. “The Core Splicing Factors EFTUD2, SNRPB and TXNL4A Are Essential for Neural Crest and Craniofacial Development.” Journal of Developmental Biology 10:29. Published July 2022. DOI/URL: https://doi.org/10.3390/jdb10030029. This provides the principal TXNL4A Xenopus knockdown/rescue evidence. (park2022thecoresplicing pages 7-10, park2022thecoresplicing pages 1-2)

PMIDs were not consistently exposed by the retrieved full-text records and have therefore not been guessed. For database ingestion, they should be resolved through PubMed using the exact titles/DOIs above.

Overall evidence assessment

The causal association between biallelic TXNL4A insufficiency and BMKS is strong, based on segregation across multiple human families plus promoter assays and conserved functional evidence. The detailed WNT/TCF7L2–EMT mechanism is biologically coherent but rests principally on one-family, preprint iPSC data and should be represented as supported/provisional, not definitive. Xenopus data independently support neural-crest progenitor loss and craniofacial consequences. Clinical epidemiology, longitudinal outcome, quality of life, genotype–phenotype prediction, standardized management, and disease-modifying treatment remain major evidence gaps.

References

1. (wood2020modellingthedevelopmental pages 1-5): Katherine A. Wood, Charlie F. Rowlands, Huw B. Thomas, Steven Woods, Julieta O’Flaherty, Sofia Douzgou, Susan J. Kimber, William G. Newman, and Raymond T. O’Keefe. Modelling the developmental spliceosomal craniofacial disorder burn-mckeown syndrome using induced pluripotent stem cells. BioRxiv, May 2020. URL: https://doi.org/10.1101/2020.05.13.094029, doi:10.1101/2020.05.13.094029. This article has 30 citations.

2. (wieczorek2014compoundheterozygosityof pages 1-2): Dagmar Wieczorek, William G. Newman, Thomas Wieland, Tea Berulava, Maria Kaffe, Daniela Falkenstein, Christian Beetz, Elisabeth Graf, Thomas Schwarzmayr, Sofia Douzgou, Jill Clayton-Smith, Sarah B. Daly, Simon G. Williams, Sanjeev S. Bhaskar, Jill E. Urquhart, Beverley Anderson, James O’Sullivan, Odile Boute, Jasmin Gundlach, Johanna Christina Czeschik, Anthonie J. van Essen, Filiz Hazan, Sarah Park, Anne Hing, Alma Kuechler, Dietmar R. Lohmann, Kerstin U. Ludwig, Elisabeth Mangold, Laura Steenpaß, Michael Zeschnigk, Johannes R. Lemke, Charles Marques Lourenco, Ute Hehr, Eva-Christina Prott, Melanie Waldenberger, Anne C. Böhmer, Bernhard Horsthemke, Raymond T. O’Keefe, Thomas Meitinger, John Burn, Hermann-Josef Lüdecke, and Tim M. Strom. Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in txnl4a causes burn-mckeown syndrome. American journal of human genetics, 95 6:698-707, Dec 2014. URL: https://doi.org/10.1016/j.ajhg.2014.10.014, doi:10.1016/j.ajhg.2014.10.014. This article has 78 citations and is from a highest quality peer-reviewed journal.

3. (wieczorek2014compoundheterozygosityof pages 7-8): Dagmar Wieczorek, William G. Newman, Thomas Wieland, Tea Berulava, Maria Kaffe, Daniela Falkenstein, Christian Beetz, Elisabeth Graf, Thomas Schwarzmayr, Sofia Douzgou, Jill Clayton-Smith, Sarah B. Daly, Simon G. Williams, Sanjeev S. Bhaskar, Jill E. Urquhart, Beverley Anderson, James O’Sullivan, Odile Boute, Jasmin Gundlach, Johanna Christina Czeschik, Anthonie J. van Essen, Filiz Hazan, Sarah Park, Anne Hing, Alma Kuechler, Dietmar R. Lohmann, Kerstin U. Ludwig, Elisabeth Mangold, Laura Steenpaß, Michael Zeschnigk, Johannes R. Lemke, Charles Marques Lourenco, Ute Hehr, Eva-Christina Prott, Melanie Waldenberger, Anne C. Böhmer, Bernhard Horsthemke, Raymond T. O’Keefe, Thomas Meitinger, John Burn, Hermann-Josef Lüdecke, and Tim M. Strom. Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in txnl4a causes burn-mckeown syndrome. American journal of human genetics, 95 6:698-707, Dec 2014. URL: https://doi.org/10.1016/j.ajhg.2014.10.014, doi:10.1016/j.ajhg.2014.10.014. This article has 78 citations and is from a highest quality peer-reviewed journal.

4. (wood2020modellingthedevelopmental pages 37-41): Katherine A. Wood, Charlie F. Rowlands, Huw B. Thomas, Steven Woods, Julieta O’Flaherty, Sofia Douzgou, Susan J. Kimber, William G. Newman, and Raymond T. O’Keefe. Modelling the developmental spliceosomal craniofacial disorder burn-mckeown syndrome using induced pluripotent stem cells. BioRxiv, May 2020. URL: https://doi.org/10.1101/2020.05.13.094029, doi:10.1101/2020.05.13.094029. This article has 30 citations.

5. (park2022thecoresplicing pages 7-10): Byung-Yong Park, Melanie Tachi-Duprat, Chibuike Ihewulezi, Arun Devotta, and Jean-Pierre Saint-Jeannet. The core splicing factors eftud2, snrpb and txnl4a are essential for neural crest and craniofacial development. Journal of Developmental Biology, 10:29, Jul 2022. URL: https://doi.org/10.3390/jdb10030029, doi:10.3390/jdb10030029. This article has 27 citations.

6. (wieczorek2014compoundheterozygosityof pages 4-6): Dagmar Wieczorek, William G. Newman, Thomas Wieland, Tea Berulava, Maria Kaffe, Daniela Falkenstein, Christian Beetz, Elisabeth Graf, Thomas Schwarzmayr, Sofia Douzgou, Jill Clayton-Smith, Sarah B. Daly, Simon G. Williams, Sanjeev S. Bhaskar, Jill E. Urquhart, Beverley Anderson, James O’Sullivan, Odile Boute, Jasmin Gundlach, Johanna Christina Czeschik, Anthonie J. van Essen, Filiz Hazan, Sarah Park, Anne Hing, Alma Kuechler, Dietmar R. Lohmann, Kerstin U. Ludwig, Elisabeth Mangold, Laura Steenpaß, Michael Zeschnigk, Johannes R. Lemke, Charles Marques Lourenco, Ute Hehr, Eva-Christina Prott, Melanie Waldenberger, Anne C. Böhmer, Bernhard Horsthemke, Raymond T. O’Keefe, Thomas Meitinger, John Burn, Hermann-Josef Lüdecke, and Tim M. Strom. Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in txnl4a causes burn-mckeown syndrome. American journal of human genetics, 95 6:698-707, Dec 2014. URL: https://doi.org/10.1016/j.ajhg.2014.10.014, doi:10.1016/j.ajhg.2014.10.014. This article has 78 citations and is from a highest quality peer-reviewed journal.

7. (wieczorek2014compoundheterozygosityof pages 3-4): Dagmar Wieczorek, William G. Newman, Thomas Wieland, Tea Berulava, Maria Kaffe, Daniela Falkenstein, Christian Beetz, Elisabeth Graf, Thomas Schwarzmayr, Sofia Douzgou, Jill Clayton-Smith, Sarah B. Daly, Simon G. Williams, Sanjeev S. Bhaskar, Jill E. Urquhart, Beverley Anderson, James O’Sullivan, Odile Boute, Jasmin Gundlach, Johanna Christina Czeschik, Anthonie J. van Essen, Filiz Hazan, Sarah Park, Anne Hing, Alma Kuechler, Dietmar R. Lohmann, Kerstin U. Ludwig, Elisabeth Mangold, Laura Steenpaß, Michael Zeschnigk, Johannes R. Lemke, Charles Marques Lourenco, Ute Hehr, Eva-Christina Prott, Melanie Waldenberger, Anne C. Böhmer, Bernhard Horsthemke, Raymond T. O’Keefe, Thomas Meitinger, John Burn, Hermann-Josef Lüdecke, and Tim M. Strom. Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in txnl4a causes burn-mckeown syndrome. American journal of human genetics, 95 6:698-707, Dec 2014. URL: https://doi.org/10.1016/j.ajhg.2014.10.014, doi:10.1016/j.ajhg.2014.10.014. This article has 78 citations and is from a highest quality peer-reviewed journal.

8. (wieczorek2014compoundheterozygosityof pages 2-3): Dagmar Wieczorek, William G. Newman, Thomas Wieland, Tea Berulava, Maria Kaffe, Daniela Falkenstein, Christian Beetz, Elisabeth Graf, Thomas Schwarzmayr, Sofia Douzgou, Jill Clayton-Smith, Sarah B. Daly, Simon G. Williams, Sanjeev S. Bhaskar, Jill E. Urquhart, Beverley Anderson, James O’Sullivan, Odile Boute, Jasmin Gundlach, Johanna Christina Czeschik, Anthonie J. van Essen, Filiz Hazan, Sarah Park, Anne Hing, Alma Kuechler, Dietmar R. Lohmann, Kerstin U. Ludwig, Elisabeth Mangold, Laura Steenpaß, Michael Zeschnigk, Johannes R. Lemke, Charles Marques Lourenco, Ute Hehr, Eva-Christina Prott, Melanie Waldenberger, Anne C. Böhmer, Bernhard Horsthemke, Raymond T. O’Keefe, Thomas Meitinger, John Burn, Hermann-Josef Lüdecke, and Tim M. Strom. Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in txnl4a causes burn-mckeown syndrome. American journal of human genetics, 95 6:698-707, Dec 2014. URL: https://doi.org/10.1016/j.ajhg.2014.10.014, doi:10.1016/j.ajhg.2014.10.014. This article has 78 citations and is from a highest quality peer-reviewed journal.

9. (wood2020modellingthedevelopmental pages 24-27): Katherine A. Wood, Charlie F. Rowlands, Huw B. Thomas, Steven Woods, Julieta O’Flaherty, Sofia Douzgou, Susan J. Kimber, William G. Newman, and Raymond T. O’Keefe. Modelling the developmental spliceosomal craniofacial disorder burn-mckeown syndrome using induced pluripotent stem cells. BioRxiv, May 2020. URL: https://doi.org/10.1101/2020.05.13.094029, doi:10.1101/2020.05.13.094029. This article has 30 citations.

10. (wood2020modellingthedevelopmental pages 27-31): Katherine A. Wood, Charlie F. Rowlands, Huw B. Thomas, Steven Woods, Julieta O’Flaherty, Sofia Douzgou, Susan J. Kimber, William G. Newman, and Raymond T. O’Keefe. Modelling the developmental spliceosomal craniofacial disorder burn-mckeown syndrome using induced pluripotent stem cells. BioRxiv, May 2020. URL: https://doi.org/10.1101/2020.05.13.094029, doi:10.1101/2020.05.13.094029. This article has 30 citations.

11. (wood2020modellingthedevelopmental pages 69-74): Katherine A. Wood, Charlie F. Rowlands, Huw B. Thomas, Steven Woods, Julieta O’Flaherty, Sofia Douzgou, Susan J. Kimber, William G. Newman, and Raymond T. O’Keefe. Modelling the developmental spliceosomal craniofacial disorder burn-mckeown syndrome using induced pluripotent stem cells. BioRxiv, May 2020. URL: https://doi.org/10.1101/2020.05.13.094029, doi:10.1101/2020.05.13.094029. This article has 30 citations.

12. (wood2020modellingthedevelopmental pages 34-37): Katherine A. Wood, Charlie F. Rowlands, Huw B. Thomas, Steven Woods, Julieta O’Flaherty, Sofia Douzgou, Susan J. Kimber, William G. Newman, and Raymond T. O’Keefe. Modelling the developmental spliceosomal craniofacial disorder burn-mckeown syndrome using induced pluripotent stem cells. BioRxiv, May 2020. URL: https://doi.org/10.1101/2020.05.13.094029, doi:10.1101/2020.05.13.094029. This article has 30 citations.

13. (wood2020modellingthedevelopmental pages 21-24): Katherine A. Wood, Charlie F. Rowlands, Huw B. Thomas, Steven Woods, Julieta O’Flaherty, Sofia Douzgou, Susan J. Kimber, William G. Newman, and Raymond T. O’Keefe. Modelling the developmental spliceosomal craniofacial disorder burn-mckeown syndrome using induced pluripotent stem cells. BioRxiv, May 2020. URL: https://doi.org/10.1101/2020.05.13.094029, doi:10.1101/2020.05.13.094029. This article has 30 citations.

14. (park2022thecoresplicing pages 4-7): Byung-Yong Park, Melanie Tachi-Duprat, Chibuike Ihewulezi, Arun Devotta, and Jean-Pierre Saint-Jeannet. The core splicing factors eftud2, snrpb and txnl4a are essential for neural crest and craniofacial development. Journal of Developmental Biology, 10:29, Jul 2022. URL: https://doi.org/10.3390/jdb10030029, doi:10.3390/jdb10030029. This article has 27 citations.

15. (park2022thecoresplicing pages 1-2): Byung-Yong Park, Melanie Tachi-Duprat, Chibuike Ihewulezi, Arun Devotta, and Jean-Pierre Saint-Jeannet. The core splicing factors eftud2, snrpb and txnl4a are essential for neural crest and craniofacial development. Journal of Developmental Biology, 10:29, Jul 2022. URL: https://doi.org/10.3390/jdb10030029, doi:10.3390/jdb10030029. This article has 27 citations.

16. (wood2020modellingthedevelopmental pages 45-49): Katherine A. Wood, Charlie F. Rowlands, Huw B. Thomas, Steven Woods, Julieta O’Flaherty, Sofia Douzgou, Susan J. Kimber, William G. Newman, and Raymond T. O’Keefe. Modelling the developmental spliceosomal craniofacial disorder burn-mckeown syndrome using induced pluripotent stem cells. BioRxiv, May 2020. URL: https://doi.org/10.1101/2020.05.13.094029, doi:10.1101/2020.05.13.094029. This article has 30 citations.

17. (park2022thecoresplicing pages 2-4): Byung-Yong Park, Melanie Tachi-Duprat, Chibuike Ihewulezi, Arun Devotta, and Jean-Pierre Saint-Jeannet. The core splicing factors eftud2, snrpb and txnl4a are essential for neural crest and craniofacial development. Journal of Developmental Biology, 10:29, Jul 2022. URL: https://doi.org/10.3390/jdb10030029, doi:10.3390/jdb10030029. This article has 27 citations.

Artifacts

• Edison artifact artifact-00